Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction

Sara Fuchs, Tali Feferman, Roberto Meidler, Raanan Margalit, Camille Sicsic, Talma Brenner, Orgad Laub, Miriam C. Souroujon

פרסום מחקרי: פרק בספר / בדוח / בכנספרסום בספר כנסביקורת עמיתים


Intravenous immunoglobulin (IVIG) administration has been beneficially used for the treatment of a variety of autoimmune diseases including myasthenia gravis (MG). We have demonstrated that IVIG administration in experimental autoimmune MG (EAMG) results in suppression of disease that is accompanied by decreased Th1 cell and B cell proliferation. Chromatography of pooled human immunoglobulins (IVIG) on immobilized IgG, isolated from rats with EAMG or from MG patients, results in a depletion of the suppressive activity of the IVIG. Moreover, reconstitution of the activity-depleted IVIG with the eluted minute IVIG fractions that had been adsorbed onto the EAMG- or MG-specific columns recovers the depleted immunosuppressive activity. This study supports the notion that the therapeutic effect of IVIG is mediated by an antigen-specific anti-immunoglobulin (anti-idiotypic) activity that is essential for its suppressive activity.

שפה מקוריתאנגלית
כותר פרסום המארחMyasthenia Gravis and Related Disorders 11th International Conference
מוציא לאורBlackwell Publishing Inc.
מספר עמודים5
מסת"ב (מודפס)9781573316873
מזהי עצם דיגיטלי (DOIs)
סטטוס פרסוםפורסם - יוני 2008

סדרות פרסומים

שםAnnals of the New York Academy of Sciences
ISSN (מודפס)0077-8923
ISSN (אלקטרוני)1749-6632

טביעת אצבע

להלן מוצגים תחומי המחקר של הפרסום 'Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction'. יחד הם יוצרים טביעת אצבע ייחודית.

פורמט ציטוט ביבליוגרפי